Skip to main content

GlycoMark Inks Diabetes Test Agreement With Premier Medical

NEW YORK (360Dx) — GlycoMark announced on Tuesday that it has signed a promotional agreement for its blood-based diabetes test with Premier Medical Laboratory Services (PMLS).

According to GlycoMark — a New York City-based joint venture between Japan's Toyota Tsusho and Nippon Kayaku — the non-fasting blood test is US Food and Drug Administration approved for detecting recent hyperglycemia and hyperglycemic excursions occurring in the prior one to two weeks in patients with diabetes. The test works by measuring levels of 1,5-anhydroglucitol, a sugar similar to glucose that is found in many foods.

Under the terms of the deal, Greenville, South Carolina-based PMLS' sales organization will promote and offer the GlycoMark test to the lab's physician network. PMLS will also add the test to its MD DiabeticPro test panel. Additional terms were not disclosed.

"By adding the GlycoMark test to PMLS' MD DiabeticPro menu, physicians will have increased awareness and access to the test to help improve the management of patients with diabetes," GlycoMark President Hiro Ishibashi said in a statement.